Once again screening for ovarian cancer has proved to be elusive. This trial, the largest ever, commenced in 2001 and recruiting until 2005 had more than 200,000 participants.
There were three different groups; about 50,000 women were allocated to a regime of measurement of serum CA125; a known marker for ovarian cancer and other disease. The frequency of testing was determined by risk, an algorithm (risk ovarian cancer algorithm ROCA) was used.
The other two groups were about 50,000 women having annual pelvic ultrasound scans with 100,000 women being in the control group, having no screening. The target for success was decrease in death from ovarian cancer. No difference was seen in the likelihood of death from ovarian cancer for any of the investigation groups. There is still a great need for reliable ovarian cancer screening.
No comments:
Post a Comment